Lexicon Pharmaceuticals’ clinical trial LX1032 for carcinoid syndrome will be among the clinical programs that are reviewed in-depth on April 8, 2010 when the company holds its Annual R&D Day from 7:30 to 11:00 am, Eastern Time, in New York City. A live webcast of the event can be accessed on Lexicon’s corporate website, http://www.lexicon-genetics.com/, and an archived version of the webcast will be available after the event.
LX1032 is Lexicon’s oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The drug is designed to reduce serotonin production in patients with metastatic carcinoid tumors. It was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. The Phase 2 clinical trial for LX1032 is a four-week, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. Among the sites where the clinical trial is being conducted are M.D. Anderson Cancer Center in Houston, Texas; the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida; and Hematology and Oncology Services of Little Rock, Arkansas.
For further information about the clinical trial go to http://www.clinicaltrials.gov. For more information about clinical trials for carcinoid cancer/NET patients, click here: http://clinicaltrials.gov/ct/search?term=carcinoid+tumors&submit=Search.
